Related Experiment Video

Updated: Jun 14, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K

[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]

Erwann Collomb1, Carolyne Croizier2

  • 1Service d'hématologie et de thérapie cellulaire, hôpital de la Conception, AP-HM, Marseille, France.

Bulletin Du Cancer
|September 3, 2024
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Anticorps bispécifiqueBCMABispecific T-cell engagerMultiple myelomaMyélome multipleRechuteRelapse

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Related Experiment Videos

Last Updated: Jun 14, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

[Burkitt lymphoma: Definition, diagnostic approach, and current therapeutic strategies].

Bulletin du cancer·2026

Factors influencing front line treatment of chronic lymphocytic leukemia: A French real-world study.

Cancer·2026

["AMM updates" section of the journal Bulletin du Cancer: Feedback from the contributing authors].

Bulletin du cancer·2026

[Studying daratumumab's interference in serum protein electrophoresis: two case reports].

Annales de biologie clinique·2025

Contribution of molecular characterization to the diagnosis of MPN in patients with low JAK2V617F variant allelic fraction in a real-world cohort.

Annals of hematology·2025

Multiplex digital PCR enables sensitive detection of resistance to BTK inhibitors.

Annals of hematology·2025

[Sarcopenia in gastrointestinal oncology: Diagnostic criteria, clinical implications and management].

Bulletin du cancer·2026

[Tenosyovial giant cell tumor (TGCT): From the physiopathology to the emergence of new targeted therapies].

Bulletin du cancer·2026

[Management of venous thromboembolism in children with acute lymphoblastic leukemia: Recommendations from the harmonization workshops of the Leukemia Committee of the French Society for Childhood Cancer (SFCE)].

Bulletin du cancer·2026

Hospitalization at home use analysis for immune checkpoint inhibitors administrations in France: Care pathways, costs and development opportunities.

Bulletin du cancer·2026

[Oncogenetics and molecular tumor boards in private practice: Specificities and perspectives].

Bulletin du cancer·2026

Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies.

Bulletin du cancer·2026

Outcome-Guided Immunosuppressive Therapy and Clinical Events in Patients With Cardiac Sarcoidosis: An Observational Registry.

Journal of the American Heart Association·2026

Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.

Cancer discovery·2026

Rituximab as Salvage Therapy in Difficult-to-Treat Autoimmune Hepatitis: A Prospective Case Series.

Gastro hep advances·2026

Spatial Transcriptomics and Mechanisms of Immune Checkpoint Inhibitor-Associated Interstitial Nephritis.

Kidney international reports·2026

Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.

Frontiers in pharmacology·2026

FcRn Inhibition in Autoantibody-Mediated Autoimmune Diseases: From Broad Immunosuppression to Precision IgG Modulation.

Mediterranean journal of rheumatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us